Lillian Kim

Lillian Kim

Lillian Kim is an associate in the firm’s Business Law Department and a member of its Technology Companies + Life Sciences Group. Ms. Kim focuses her practice on advising private and public companies in a variety of transactions, including mergers, acquisitions, tender offers, divestitures, joint ventures and corporate governance matters. She has represented clients across a broad range of industries, including healthcare, software, information technology, financial services, retail and consumer products, pharmaceuticals and biotechnology.


Ms. Kim’s recent representations include:

  • Thar Pharmaceuticals, a biopharmaceutical company, in its acquisition by an affiliate of The Grünenthal Group
  • Imprivata in its $544 million sale to Thoma Bravo
  • Opower in its $532 million sale to Oracle
  • Ocata Therapeutics in its $380 million sale to Astellas Pharma
  • FutureAdvisor in its acquisition by BlackRock
  • Teva Pharmaceuticals in its acquisition of Auspex Pharmaceuticals
  • JMI Equity portfolio company, Compusearch, in its sale to ABRY Partners

Prior to joining Goodwin, Ms. Kim practiced with Fried, Frank, Harris, Shriver & Jacobson LLP and Linklaters LLP.


While attending law school, Ms. Kim was a senior editor for the University of Pennsylvania Journal of Business Law.



J.D., 2010
University of Pennsylvania Law School
The Wharton School at the University of Pennsylvania
B.A., 2004
Wellesley College



New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers